Pharmacy Prior Authorization

Any pharmaceutical not listed on our formulary requires prior authorization. For self-administered drugs requiring prior authorization, please contact Express Scripts at 1-844-605-8168 or use https://www.CoverMyMeds.com to start the prior authorization process.

START THE PROCESS

Formularies and Pharmacies for 2019 Plans

Step Therapy Criteria

Pharmacy Forms, Programs, and Policies

Professionally Administered Drugs

CHPW requires prior authorization for certain professionally administered medications. MCG guidelines are used to determine medical necessity in the absence of CHPW Clinical Coverage Criteria. You can review our utilization management guidelines and policies for medical drug benefits by visiting our Professionally Administered Drug page.

New Limits for Opioid Prescriptions from CMS

Starting on January 1, 2019, there will be new limits on opioid prescriptions for members who have Medicare Part D. This change follows guidance from the Centers for Medicare & Medicaid Services (CMS).

  • Members who are filling a first-time prescription for opioids to treat acute pain won’t be able to get more than a seven-day supply at one time.
  • Pharmacists will be required to consult with the prescriber for opioid prescriptions greater than 90 morphine equivalent dose (MME) per day.

These limits don’t apply to members who:

  • Live in a long-term care facility.
  • Are in hospice and receiving end-of-life care.
  • Are being treated for active cancer-related pain.
  • Are prescribed buprenorphine products for medically assisted treatment (MAT).

More oversight

CMS recommends more oversight and monitoring of opioid prescription to address current trends and safety concerns. Medication reviews may result in a member being assigned to a single pharmacy and a single subscriber for controlled substances in order to better coordinate care and case management.

To read more about changes to opioid prescriptions for Medicare Part D members in 2019, please see the CMS Factsheet: https://www.cms.gov

DID YOU KNOW...?

DRUG RECALL: VALSARTAN, VALSARTAN-HYDROCLOROTHIAZIDE & AMLODIPINE – VALSARTAN

Group of doctors and nurses looking to and discussing x-ray image at clinic.On 12/31/2018, Aurobindo Pharma USA, Inc. recalled Amlodipine-Valsartan, Valsartan-HCTZ, and Valsartan tablets due to the detection of trace amounts of an unexpected impurity found in the finished drug product.   To date, Aurobindo Pharma USA, Inc. has not received any reports of adverse events related to this recall.

Recalled Drug: Valsartan 320mg tablets, Amlodipine-Valsartan 5/160mg, 5/320mg, 10/160mg,    10/320mg tablets , and Valsartan & Hydrochlorothiazide 80/12.5mg, 160/12.5mg, 160/25mg, 320/12.5mg and 320/25mg tablets

Lot Numbers: Aurobindo Pharma USA, Inc. has 80 different lots of medications affected in this recall. Please refer to the link above for more information on the National Drug Code (NDC), expiration date and lot number that corresponds with your medication. More information about the recall is available at: http://www.fda.gov/Safety/Recalls/EnforcementReports/default.htm.

☏ HAVE QUESTIONS ?

Sales Team

Get real answers
from real people

Phone: 1-800-944-1247
Email: Sales@chpw.org

x